FilingReader Intelligence

Southern Shuanglin Bio-Pharmacy halts trading amid control change plans

June 9, 2025 at 10:07 PM UTCBy FilingReader AI

Southern Shuanglin Bio-Pharmacy announced a trading halt of its shares (SZSE:000403), effective today, June 6, 2025. The suspension is due to ongoing planning regarding a potential change in control of the company. According to the announcement, the major shareholder, Gongqingcheng Shengbang Yinghao Investment Partnership (Limited Partnership) is planning matters relating to the change in control. The company anticipates the trading halt will not exceed two trading days. Southern Shuanglin Bio-Pharmacy advises investors to be aware of potential investment risks due to the uncertainty surrounding the change of control. The company will disclose further information through official announcements in the Securities Times and on the CNINFO website.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SZSE:000403Shenzhen Stock Exchange
Pharmaceuticals

News Alerts

Get instant email alerts when Southern Shuanglin Bio-Pharmacy publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →